Business Context and Reporting Period
This Form 8-K is a current report filed by Enochian Biosciences Inc. (not Lunai Bioworks Inc.) on March 25, 2022. The filing addresses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
Departure of Director: On March 25, 2022, Carl Sandler resigned as a member of the Board of Directors. The resignation was effective immediately.
- Reason: To focus on other business ventures.
- Disagreement: The company explicitly states the decision was not the result of any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the standard disclosure of the director's departure.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Mr. Sandler's resignation.
- Confirm whether a replacement director has been appointed or if the board is operating with a vacancy.
- Review recent 10-K or 10-Q filings for the most up-to-date financial metrics, as this 8-K does not contain them.